



# Model List of Essential Medicines

## Amikacin

Section	Indications
<p><b>Access group antibiotics</b></p> <p>Parenteral &gt; General injections &gt; unspecified: 250 mg per mL in 2 mL vial (as sulfate)</p>	<p><b>First choice</b></p> <p>co-prescribed with <b>cefotaxime</b></p> <div style="border: 1px solid #ccc; padding: 5px; display: inline-block;">Acute pyelonephritis (severe)</div> <p>co-prescribed with <b>ceftriaxone</b></p> <div style="border: 1px solid #ccc; padding: 5px; display: inline-block;">Acute pyelonephritis (severe)</div> <p><b>Second choice</b></p> <p>co-prescribed with <b>cloxacillin</b></p> <div style="border: 1px solid #ccc; padding: 5px; display: inline-block;">Sepsis without septic shock</div>
<p><b>Antituberculosis medicines</b></p> <p>Parenteral &gt; General injections &gt; unspecified: 250 mg per mL in 2 mL vial (as sulfate)</p>	<div style="border: 1px solid #ccc; padding: 5px; display: inline-block;">Multi-drug resistant Mycobacterium tuberculosis</div>

## Amoxicillin

Section	Indications
<p><b>Access group antibiotics</b></p> <p>Oral &gt; Liquid: 125 mg per 5 mL (anhydrous) powder for oral liquid; 250 mg per 5 mL (anhydrous) powder for oral liquid</p> <p>Oral &gt; Solid: 250 mg (anhydrous) capsule or tablet; 500 mg (anhydrous) capsule or tablet</p> <p>Oral &gt; Liquid: 125 mg per 5 mL (as trihydrate) powder for oral liquid; 250 mg per 5 mL (as trihydrate) powder for oral liquid</p> <p>Oral &gt; Solid: 250 mg (as trihydrate); 500 mg (as trihydrate)</p> <p>Parenteral &gt; General injections &gt; unspecified: 250 mg in vial (as sodium) powder for injection; 500 mg in vial (as sodium) powder for injection; 1 g in vial (as sodium) powder for injection</p>	<p><b>First choice</b></p> <div style="border: 1px solid #ccc; padding: 5px; display: inline-block;">Chronic obstructive pulmonary disease with acute exacerbation</div> <p>co-prescribed with <b>gentamicin</b></p> <div style="border: 1px solid #ccc; padding: 5px; display: inline-block;">Sepsis without septic shock</div> <p><b>Other indications</b></p> <div style="border: 1px solid #ccc; padding: 5px; display: inline-block;">Bacterial infection of unspecified site</div> <div style="border: 1px solid #ccc; padding: 5px; display: inline-block;">Infectious cystitis</div>

## Amoxicillin + clavulanic acid

Section	Indications
<b>Access group antibiotics</b>  Parenteral > General injections > IV: 500 mg (as sodium salt) + 100 mg (as potassium salt) powder for injection; 1000 mg (as sodium salt) + 200 mg (as potassium salt) powder for injection  Oral > Solid: 500 mg (as trihydrate) + 125 mg (as potassium salt)  Oral > Liquid: 250 mg + 62.5 mg per 5 mL powder for oral liquid; 125 mg + 31.25 mg per 5 mL powder for oral liquid  Oral > Solid: 500 mg + 125 mg tablet  Oral > Liquid: 125 mg (as trihydrate) + 31.25 mg (as potassium salt) powder for oral liquid; 250 mg (as trihydrate) + 62.5 mg (as potassium salt) powder for oral liquid  Oral > Solid: 500 mg (as trihydrate) + 125 mg (as potassium salt); 875 mg (as trihydrate) + 125 mg (as potassium salt)  Oral > Solid > dispersible tablet: 200 mg (as trihydrate) + 28.5 mg (as potassium salt); 250 mg (as trihydrate) + 62.5 mg (as potassium salt)	<b>First choice</b>  <a href="#">Infectious cystitis</a>  <a href="#">Chronic obstructive pulmonary disease with acute exacerbation</a>  <b>Other indications</b>  <a href="#">Bacterial infection of unspecified site</a>
<b>Antituberculosis medicines</b>  Oral > Liquid: 250 mg (as trihydrate) + 62.5 mg per 5 mL (as potassium salt) powder for oral liquid  Oral > Solid: 500 mg (as trihydrate) + 125 mg (as potassium salt)	<a href="#">Multi-drug resistant Mycobacterium tuberculosis</a>

## Ampicillin

Section	Indications
Access group antibiotics	
Parenteral > General injections > unspecified: 500 mg in vial (as sodium salt) powder for injection; 1 g in vial (as sodium salt) powder for injection	First choice co-prescribed with <a href="#">gentamicin</a>
Oral > Liquid: 125 mg per 5 mL (anhydrous) powder for oral suspension	<a href="#">Peritoneal abscess (severe)</a> co-prescribed with <a href="#">gentamicin</a>
Oral > Solid: 250 mg (anhydrous); 500 mg (anhydrous)	<a href="#">Sepsis without septic shock</a> co-prescribed with <a href="#">gentamicin</a>
	<a href="#">Peritoneal abscess (mild-moderate)</a> co-prescribed with <a href="#">gentamicin</a>
	<a href="#">Peritonitis (severe)</a> co-prescribed with <a href="#">gentamicin</a>
	<a href="#">Acute malnutrition in infants, children or adolescents (complicated) [children]</a> co-prescribed with <a href="#">gentamicin</a>
	<a href="#">Peritonitis (mild-moderate)</a> co-prescribed with <a href="#">gentamicin</a>
	<a href="#">Bacterial pneumonia (Community-acquired pneumonia - severe) [children]</a>
Second choice	
	<a href="#">Bacterial meningitis</a>
Other indications	
	<a href="#">Bacterial infection of unspecified site</a>

## Azithromycin

Section	Indications
Watch group antibiotics	
Oral > Liquid: 200 mg per 5 mL oral liquid	First choice co-prescribed with <a href="#">ceftriaxone</a>
Oral > Solid: 250 mg (anhydrous) capsule; 500 mg (anhydrous) capsule	<a href="#">Gonococcal infection</a>
Second choice	
	co-prescribed with <a href="#">cefixime</a>
	<a href="#">Gonococcal infection</a>

## Aztreonam

Section	Indications
Reserve group antibiotics	<a href="#">Other specified bacterial diseases</a>
Parenteral > General injections > unspecified: 1 g in vial powder for injection; 2 g in vial powder for injection	

## Bedaquiline

Section	Indications
Antituberculosis medicines Oral > Solid: 100 mg tablet; 20 mg tablet	Multi-drug resistant Mycobacterium tuberculosis

## Benzathine benzylpenicillin

Section	Indications
Access group antibiotics Parenteral > General injections > IM: 900 mg in vial benzylpenicillin powder for injection (= 1.2 million IU); 1.44 g in vial benzylpenicillin powder for injection (= 2.4 million IU)	First choice Syphilis Congenital syphilis [children]
	Other indications Bacterial infection of unspecified site

## Benzylpenicillin

Section	Indications
Access group antibiotics Parenteral > General injections > unspecified: 600 mg in vial powder for injection (= 1 million IU as sodium or potassium salt); 3 g in vial powder for injection (= 5 million IU as sodium or potassium salt)  Parenteral > General injections > unspecified: 600 mg in vial powder for injection (= 1 million IU as sodium or potassium salt); 3 g in vial powder for injection (= 5 million IU as sodium or potassium salt)	First choice Congenital syphilis [children] Syphilis co-prescribed with gentamicin Sepsis without septic shock co-prescribed with gentamicin Acute malnutrition in infants, children or adolescents (complicated) [children] co-prescribed with gentamicin Bacterial pneumonia (Community-acquired pneumonia - severe) [children] Second choice Bacterial meningitis Other indications Bacterial infection of unspecified site

## Capreomycin

Section	Indications
Antituberculosis medicines Parenteral > General injections > IV: 1000 mg powder for injection (vial)	Multi-drug resistant Mycobacterium tuberculosis

## Cefalexin

Section	Indications
Access group antibiotics	
Oral > Liquid: 125 mg per 5 mL (anhydrous) powder for oral liquid; 250 mg per 5 mL (anhydrous) powder for oral liquid	Second choice Chronic obstructive pulmonary disease with acute exacerbation
Oral > Solid: 250 mg (as monohydrate)	Other indications
Oral > Solid: 250 mg (as monohydrate); 500 mg (as monohydrate)	Bacterial infection of unspecified site

## Cefazolin

Section	Indications
Access group antibiotics	
Parenteral > General injections > unspecified: 1 g in vial (as sodium salt) powder for injection	First choice Other specified prophylactic measures co-prescribed with metronidazole Other specified prophylactic measures
	Second choice Osteomyelitis or osteitis Bacterial infection of joint
	Other indications Surgical site infection

## Cefepime

Section	Indications
Watch group antibiotics	Other specified bacterial diseases

## Cefixime

Section	Indications
Watch group antibiotics	
Oral > Liquid: 100 mg per 5 mL powder for oral liquid	Second choice Infectious gastroenteritis or colitis without specification of infectious agent
Oral > Solid: 200 mg (as trihydrate); 400 mg (as trihydrate)	co-prescribed with azithromycin Gonococcal infection

## Cefotaxime

Section	Indications
Watch group antibiotics Parenteral > General injections > unspecified: 250 mg in vial powder for injection (as sodium salt)	Bacterial infection of unspecified site

## Ceftaroline

Section	Indications
Reserve group antibiotics Parenteral > General injections > IV: 400 mg in vial (as fosamil) powder for injection; 600 mg in vial (as fosamil) powder for injection	Other specified bacterial diseases

## Ceftazidime

Section	Indications
Watch group antibiotics Parenteral > General injections > unspecified: 250 mg in vial (as pentahydrate) powder for injection; 1 g in vial (as pentahydrate) powder for injection	First choice co-prescribed with vancomycin
	Endophthalmitis
	Other indications
	Pseudomonas aeruginosa resistant to other antibiotic

## Ceftazidime + avibactam

Section	Indications
Reserve group antibiotics Parenteral > General injections > IV: 2 g in vial + 0.5 g in vial powder for injection	Carbapenem-resistant Pseudomonas aeruginosa
	Carbapenem resistant Enterobacteriales

## Ceftolozane + tazobactam

Section	Indications
Reserve group antibiotics Parenteral > General injections > IV: 1 g + 0.5 g powder for injection	Carbapenem-resistant Pseudomonas aeruginosa

## Ceftriaxone

Section	Indications
<p><b>Watch group antibiotics</b></p> <p>Parenteral &gt; General injections &gt; unspecified: 250 mg in vial powder for injection (as sodium salt); 1 g in vial powder for injection (as sodium salt)</p> <p>Parenteral &gt; General injections &gt; unspecified: 250 mg in vial powder for injection (as sodium salt); 1 g in vial powder for injection (as sodium salt); 2 g in vial powder for injection (as sodium salt)</p>	<p><b>First choice</b></p> <p>co-prescribed with <a href="#">metronidazole</a></p> <p><a href="#">Necrotising fasciitis</a></p> <p><b>Other indications</b></p> <p><a href="#">Bacterial infection of unspecified site</a></p>

## Cefuroxime

Section	Indications
<p><b>Watch group antibiotics</b></p> <p>Parenteral &gt; General injections &gt; IV: 250 mg in vial (as sodium salt) powder for injection; 750 mg in vial (as sodium salt) powder for injection; 1.5 g in vial (as sodium salt) powder for injection</p>	<p><b>Second choice</b></p> <p><a href="#">Other specified prophylactic measures</a></p>

## Chloramphenicol

Section	Indications
<p><b>Access group antibiotics</b></p> <p>Parenteral &gt; General injections &gt; IV: 1 g in vial powder for injection (sodium succinate)</p> <p>Parenteral &gt; General injections &gt; IM: 500 mg in 2 mL ampoule oily suspension for injection</p> <p>Oral &gt; Liquid: 150 mg per 5 mL (as palmitate)</p> <p>Oral &gt; Solid: 250 mg capsule</p>	<p><a href="#">Bacterial infection of unspecified site</a></p>

## Ciprofloxacin

Section	Indications
<p><b>Watch group antibiotics</b></p> <p>Parenteral &gt; General injections &gt; IV: 2 mg per mL (as hyclate)</p> <p>Oral &gt; Liquid: 250 mg per 5 mL (anhydrous)</p> <p>Oral &gt; Solid: 250 mg (as hydrochloride)</p> <p>Oral &gt; Solid: 250 mg (as hydrochloride); 500 mg (as hydrochloride)</p>	<p><b>First choice</b></p> <p><a href="#">Inflammatory and other diseases of prostate (mild to moderate)</a></p> <p><b>Other indications</b></p> <p><a href="#">Bacterial infection of unspecified site</a></p>

## Clindamycin

Section	Indications
Access group antibiotics	Bacterial infection of unspecified site
Oral > Liquid: 75 mg per 5 mL (as palmitate hydrochloride)	
Oral > Solid: 150 mg (as hydrochloride) capsule	
Parenteral > General injections > unspecified: 150 mg per mL (as phosphate) injection	

## Clofazimine

Section	Indications
Antituberculosis medicines	Multi-drug resistant Mycobacterium tuberculosis
Oral > Solid: 100 mg; 50 mg	
Antileprosy medicines	Leprosy
Oral > Solid: 100 mg; 50 mg	

## Cloxacillin

Section	Indications
Access group antibiotics	Bacterial infection of unspecified site
Oral > Liquid: 125 mg per 5 mL (as sodium salt) powder for oral liquid	
Oral > Solid: 500 mg (as sodium salt) capsule; 1 g (as sodium salt) capsule	
Parenteral > General injections > unspecified: 500 mg in vial (as sodium salt) powder for injection	

## Colistin (injection)

Section	Indications
Reserve group antibiotics	Other specified bacterial diseases
Parenteral > General injections > unspecified: 1 million IU in vial (as colistemethate sodium)	

## Cycloserine

Section	Indications
Antituberculosis medicines	Multi-drug resistant Mycobacterium tuberculosis
Oral > Solid: 250 mg; 125 mg	

## Dapsone

Section	Indications
Antileprosy medicines	Leprosy
Oral > Solid: 100 mg tablet; 50 mg tablet; 25 mg tablet	

## Daptomycin

Section	Indications
Reserve group antibiotics Parenteral > General injections > IV: 350 mg in vial powder for injection; 500 mg in vial powder for injection	Other specified bacterial diseases

## Delaflloxacin

Section	Indications
Watch group antibiotics Parenteral > General injections > IV: 300 mg lyophilized powder for injection Oral > Solid: 450 mg	Methicillin resistant <i>Staphylococcus aureus</i>

## Delamanid

Section	Indications
Antituberculosis medicines Oral > Solid: 50 mg tablet; 25 mg tablet (dispersible)	Multi-drug resistant <i>Mycobacterium tuberculosis</i>

## Doxycycline

Section	Indications
Access group antibiotics Oral > Solid: 100 mg (as hyolate) Parenteral > General injections > unspecified: 100 mg in vial powder for injection Oral > Liquid: 25 mg per 5 mL (anhydrous); 50 mg per 5 mL (anhydrous) Oral > Solid: 100 mg (as hyolate); 50 mg (as hyolate)	<p>First choice <i>Chlamydia trachomatis</i></p> <p>Second choice <i>Chronic obstructive pulmonary disease with acute exacerbation</i></p> <p>Other indications <i>Bacterial infection of unspecified site</i></p>

## Eravacycline

Section	Indications
Reserve group antibiotics Parenteral > General injections > IV: 50 mg lyophilized powder for injection	<i>Carbapenem resistant Enterobacterales</i>

## Erythromycin

Section	Indications
<p><b>Watch group antibiotics</b></p> <p>Parenteral &gt; General injections &gt; IV: 500 mg in vial powder for injection (as lactobionate)</p> <p>Oral &gt; Liquid: 125 mg per 5 mL (as stearate or ethylsuccinate)</p> <p>Oral &gt; Solid: 250 mg (as stearate or ethylsuccinate)</p>	Bacterial infection of unspecified site

## Ethambutol

Section	Indications
<p><b>Antituberculosis medicines</b></p> <p>Parenteral &gt; General injections &gt; IV: 1000 mg per 10 mL; 2000 mg per 20 mL</p>	Other specified tuberculosis
Oral > Solid: 100 mg (hydrochloride); 400 mg (hydrochloride); 100 mg tablet (dispersible)	Tuberculosis

## Ethambutol + isoniazid

Section	Indications
<p><b>Antituberculosis medicines</b></p> <p>Oral &gt; Solid: 400 mg + 150 mg tablet</p>	Tuberculosis

## Ethambutol + isoniazid + pyrazinamide + rifampicin

Section	Indications
<p><b>Antituberculosis medicines</b></p> <p>Oral &gt; Solid: 275 mg + 75 mg + 400 mg + 150 mg tablet</p>	Tuberculosis

## Ethambutol + isoniazid + rifampicin

Section	Indications
<p><b>Antituberculosis medicines</b></p> <p>Oral &gt; Solid: 275 mg + 75 mg + 150 mg tablet</p>	Tuberculosis

## Ethionamide

Section	Indications
<p><b>Antituberculosis medicines</b></p> <p>Oral &gt; Solid: 250 mg tablet; 125 mg tablet (dispersible)</p>	Multi-drug resistant Mycobacterium tuberculosis Tuberculous meningitis

## Fifth generation cephalosporins

Section	Indications
Reserve group antibiotics	Other specified bacterial diseases

## Fosfomycin (injection)

Section	Indications
Reserve group antibiotics  Parenteral > General injections > IV: 2 g in vial (as sodium) powder for injection; 4 g in vial (as sodium) powder for injection	Other specified bacterial diseases  Carbapenem resistant <i>Acinetobacter baumannii</i>  Carbapenem-resistant <i>Pseudomonas aeruginosa</i>  Carbapenem resistant <i>Enterobacteriales</i>

## Fourth generation cephalosporins

Section	Indications
Watch group antibiotics	Other specified bacterial diseases

## Gatifloxacin

Section	Indications
Antituberculosis medicines  Oral > Solid: 200 mg; 400 mg	Multi-drug resistant <i>Mycobacterium tuberculosis</i>

# Gentamicin

Section	Indications
Access group antibiotics	
Parenteral > General injections > unspecified: 10 mg per mL in 2 mL vial (as sulfate); 40 mg per mL in 2 mL vial (as sulfate)	<b>First choice</b>  <b>Neonatal meningitis</b> co-prescribed with <b>amoxicillin</b>  <b>Bacterial pneumonia (Community-acquired pneumonia - severe) [children]</b> co-prescribed with <b>amoxicillin</b>  <b>Sepsis without septic shock</b> co-prescribed with <b>ampicillin</b>  <b>Acute malnutrition in infants, children or adolescents (complicated) [children]</b> co-prescribed with <b>ampicillin</b>  <b>Peritonitis (mild-moderate)</b> co-prescribed with <b>ampicillin</b>  <b>Peritonitis (severe)</b> co-prescribed with <b>ampicillin</b>  <b>Peritoneal abscess (severe)</b> co-prescribed with <b>ampicillin</b>  <b>Sepsis without septic shock</b> co-prescribed with <b>ampicillin</b>  <b>Bacterial pneumonia (Community-acquired pneumonia - severe) [children]</b> co-prescribed with <b>ampicillin</b>  <b>Peritoneal abscess (mild-moderate)</b> co-prescribed with <b>benzylpenicillin</b>  <b>Acute malnutrition in infants, children or adolescents (complicated) [children]</b> co-prescribed with <b>benzylpenicillin</b>  <b>Sepsis without septic shock</b> co-prescribed with <b>benzylpenicillin</b>  <b>Bacterial pneumonia (Community-acquired pneumonia - severe) [children]</b>
	<b>Second choice</b>  <b>Other specified prophylactic measures</b>  <b>Gonococcal infection</b>
	<b>Other indications</b>  <b>Bacterial infection of unspecified site</b>

## Imipenem + cilastatin

Section	Indications
Watch group antibiotics  Parenteral > General injections > IV: 250 mg (as monohydrate) + 250 mg (as sodium salt) powder for injection; 500 mg (as monohydrate) + 500 mg (as sodium salt) powder for injection	Second choice  Therapeutic equivalent to <a href="#">meropenem</a> for  <a href="#">Neutropenia (high-risk)</a>  Therapeutic equivalent to <a href="#">meropenem</a> for  <a href="#">Peritoneal abscess (severe)</a>  Therapeutic equivalent to <a href="#">meropenem</a> for  <a href="#">Peritonitis (severe)</a>
Antituberculosis medicines	Other indications  <a href="#">Pseudomonas aeruginosa resistant to other antibiotic</a>  <a href="#">Antibiotic resistant Acinetobacter baumannii</a>  Therapeutic equivalent to <a href="#">meropenem</a> for  <a href="#">Multi-drug resistant Mycobacterium tuberculosis</a>

## Imipenem + cilastatin + relebactam

Section	Indications
Reserve group antibiotics  Parenteral > General injections > IV: 500 mg + 500 mg + 250 mg powder for injection	<a href="#">Other specified other antibiotic resistant Enterobacteriales</a>  <a href="#">Carbapenem resistant Enterobacteriales</a>  <a href="#">Carbapenem-resistant Pseudomonas aeruginosa</a>

## Isoniazid

Section	Indications
Antituberculosis medicines  Parenteral > General injections > IV: 100 mg per mL  Oral > Solid: 100 mg tablet; 100 mg tablet (dispersible); 300 mg tablet	<a href="#">Other specified tuberculosis</a>  <a href="#">Tuberculosis</a>

## Isoniazid + pyrazinamide + rifampicin

Section	Indications
Antituberculosis medicines  Oral > Solid: 50 mg + 150 mg + 75 mg tablet (dispersible)	<a href="#">Tuberculosis</a>

## Isoniazid + rifampicin

Section	Indications
Antituberculosis medicines Oral > Solid: 50 mg + 75 mg tablet (dispersible); 75 mg + 150 mg tablet; 150 mg + 300 mg tablet	Tuberculosis

## Isoniazid + rifapentine

Section	Indications
Antituberculosis medicines Oral > Solid: 300 mg + 300 mg tablet (scored)	Latent tuberculosis

## Kanamycin (injection)

Section	Indications
Antituberculosis medicines Parenteral > General injections > IV: 1000 mg powder for injection (vial)	Multi-drug resistant Mycobacterium tuberculosis

## Levofloxacin

Section	Indications
Antituberculosis medicines Oral > Solid: 250 mg tablet; 500 mg tablet; 750 mg tablet; 100 mg tablet (dispersible)	Multi-drug resistant Mycobacterium tuberculosis

## Linezolid

Section	Indications
Reserve group antibiotics Parenteral > General injections > IV: 2 mg per mL in 300 mL bag Oral > Liquid: 100 mg per 5 mL powder for oral liquid Oral > Solid: 400 mg tablet; 600 mg tablet	Other specified bacterial diseases
Antituberculosis medicines Oral > Solid: 600 mg tablet; 150 mg tablet (dispersible)	Multi-drug resistant Mycobacterium tuberculosis

## Meropenem

Section	Indications
<b>Watch group antibiotics</b> Parenteral > General injections > IV: 500 mg in vial (as trihydrate) powder for injection; 1 g in vial (as trihydrate) powder for injection	Second choice <b>Neutropenia (high-risk)</b> <b>Peritoneal abscess (severe)</b> <b>Peritonitis (severe)</b> <b>Neonatal meningitis</b>
<b>Antituberculosis medicines</b> Parenteral > General injections > IV: 500 mg in vial (as trihydrate) powder for injection; 1 g in vial (as trihydrate) powder for injection	<b>Multi-drug resistant Mycobacterium tuberculosis</b>

## Meropenem + vaborbactam

Section	Indications
<b>Reserve group antibiotics</b> Parenteral > General injections > IV: 1 g in vial + 1 g in vial powder for injection	<b>Carbapenem-resistant <i>Pseudomonas aeruginosa</i></b> <b>Carbapenem resistant <i>Enterobacteriales</i></b> <b>Carbapenem resistant <i>Acinetobacter baumannii</i></b>

## Metronidazole

Section	Indications
Access group antibiotics	
Oral > Liquid: 200 mg per 5 mL (as benzoate)	First choice co-prescribed with <a href="#">cefazolin</a>
Oral > Solid: 200 to 500 mg tablet	<a href="#">Other specified prophylactic measures</a>
Parenteral > General injections > unspecified: 500 mg per 100 mL in vial Injection	co-prescribed with <a href="#">cefotaxime</a>
Local > Rectal > Suppository: 500 mg suppository; 1 g suppository	<a href="#">Peritoneal abscess (severe)</a>
	co-prescribed with <a href="#">cefotaxime</a>
	<a href="#">Peritonitis (mild-moderate)</a>
	co-prescribed with <a href="#">cefotaxime</a>
	<a href="#">Peritoneal abscess (mild-moderate)</a>
	co-prescribed with <a href="#">cefotaxime</a>
	<a href="#">Peritonitis (severe)</a>
	co-prescribed with <a href="#">ceftriaxone</a>
	<a href="#">Peritoneal abscess (severe)</a>
	co-prescribed with <a href="#">ceftriaxone</a>
	<a href="#">Peritoneal abscess (mild-moderate)</a>
	co-prescribed with <a href="#">ceftriaxone</a>
	<a href="#">Peritonitis (mild-moderate)</a>
	co-prescribed with <a href="#">ceftriaxone</a>
	<a href="#">Peritonitis (severe)</a>
	Second choice
	co-prescribed with <a href="#">ciprofloxacin</a>
	<a href="#">Peritoneal abscess (mild-moderate)</a>
	co-prescribed with <a href="#">ciprofloxacin</a>
	<a href="#">Peritonitis (mild-moderate)</a>
	Other indications
	<a href="#">Bacterial infection of unspecified site</a>

## Moxifloxacin

Section	Indications
Antituberculosis medicines	
Oral > Solid: 400 mg tablet; 100 mg tablet (dispersible)	<a href="#">Multi-drug resistant Mycobacterium tuberculosis</a>
Oral > Solid: 400 mg tablet	<a href="#">Tuberculosis</a>

## Ofloxacin

Section	Indications
Antituberculosis medicines Oral > Solid: 200 mg; 400 mg	Multi-drug resistant Mycobacterium tuberculosis

## Omadacycline

Section	Indications
Reserve group antibiotics Parenteral > General injections > IV: 100 mg lyophilized powder for injection Oral > Solid: 300 mg	Methicillin resistant <i>Staphylococcus aureus</i>

## Oxazolidinones

Section	Indications
Reserve group antibiotics	Other specified bacterial diseases

## P-aminosalicylate sodium

Section	Indications
Antituberculosis medicines Oral > Liquid: 5.52 g in sachet (equivalent to 4 g p-aminosalicylic acid)	Multi-drug resistant Mycobacterium tuberculosis

## P-aminosalicylic acid

Section	Indications
Antituberculosis medicines Oral > Solid: 4 g granules in sachet	Multi-drug resistant Mycobacterium tuberculosis

## Phenoxymethylpenicillin

Section	Indications
Access group antibiotics Oral > Liquid: 250 mg per 5 mL (as potassium salt) powder for oral liquid Oral > Solid: 250 mg (as potassium salt) tablet Oral > Solid: 250 mg (as potassium salt); 500 mg (as potassium salt)	<p>First choice</p> <ul style="list-style-type: none"><li>Acute pharyngitis</li><li>Periapical abscess without sinus</li><li>Bacterial pneumonia (Community-acquired pneumonia - mild to moderate)</li></ul> <p>Other indications</p> <ul style="list-style-type: none"><li>Bacterial infection of unspecified site</li></ul>

## Piperacillin + tazobactam

Section	Indications
<p><b>Watch group antibiotics</b></p> <p>PARENTERAL &gt; General injections &gt; IV: 2 g (as sodium salt) + 250 mg (as sodium salt) powder for injection; 4 g (as sodium salt) + 500 mg (as sodium salt) powder for injection</p>	<p><b>First choice</b></p> <ul style="list-style-type: none"><li>Peritoneal abscess (severe)</li><li>Neutropenia (high-risk)</li><li>Peritonitis (severe)</li><li>Other specified pneumonia (Hospital-acquired pneumonia)</li></ul>

## Plazomicin

Section	Indications
<p><b>Reserve group antibiotics</b></p> <p>PARENTERAL &gt; General injections &gt; IV: 500 mg per 10 mL (Injection)</p>	<ul style="list-style-type: none"><li>Carbapenem resistant <i>Acinetobacter baumannii</i></li><li>Carbapenem-resistant <i>Pseudomonas aeruginosa</i></li><li>Carbapenem resistant <i>Enterobacteriales</i></li></ul>

## Polymyxins

Section	Indications
<p><b>Reserve group antibiotics</b></p> <p>.</p>	<ul style="list-style-type: none"><li>Other specified bacterial diseases</li></ul>

## Pretomanid

Section	Indications
<p><b>Antituberculosis medicines</b></p> <p>Oral &gt; Solid &gt; tablet: 200 mg</p>	<ul style="list-style-type: none"><li>Multi-drug resistant <i>Mycobacterium tuberculosis</i></li></ul>

## Procaine benzylpenicillin

Section	Indications
<p><b>Access group antibiotics</b></p> <p>PARENTERAL &gt; General injections &gt; IM: 1 g in vial (=1 million IU) powder for injection; 3 g in vial (=3 million IU) powder for injection</p>	<p><b>First choice</b></p> <ul style="list-style-type: none"><li>Congenital syphilis [children]</li></ul> <p><b>Second choice</b></p> <ul style="list-style-type: none"><li>Syphilis</li></ul>

## Protonamide

Section	Indications
Antituberculosis medicines	Therapeutic equivalent to ethionamide for Multi-drug resistant <i>Mycobacterium tuberculosis</i>

## Pyrazinamide

Section	Indications
Antituberculosis medicines Oral > Solid: 400 mg; 150 mg tablet (dispersible); 500 mg	Tuberculosis

## Rifabutin

Section	Indications
Antituberculosis medicines Oral > Solid: 150 mg	Tuberculosis

## Rifampicin

Section	Indications
Antituberculosis medicines Oral > Liquid: 20 mg per mL Oral > Solid: 150 mg; 300 mg Parenteral > General injections > IV: 600 mg in vial powder for injection	Tuberculosis Other specified tuberculosis
Antileprosy medicines Oral > Liquid: 20 mg per mL Oral > Solid: 150 mg; 300 mg	Leprosy

## Rifapentine

Section	Indications
Antituberculosis medicines Oral > Solid: 150 mg tablet; 300 mg tablet	Tuberculosis Latent tuberculosis

## Spectinomycin

Section	Indications
Access group antibiotics Parenteral > General injections > unspecified: 2 g in vial (as hydrochloride) powder for injection	Second choice Gonococcal infection
	Other indications
	Bacterial infection of unspecified site

## Streptomycin (injection)

Section	Indications
Antituberculosis medicines Parenteral > General injections > IV: 1 g powder for injection (as sulfate) as vial	Multi-drug resistant Mycobacterium tuberculosis

## Sulfamethoxazole + trimethoprim

Section	Indications
Access group antibiotics Parenteral > General injections > IV: 80 mg + 16 mg per mL in 10 mL ampoule; 80 mg + 16 mg per mL in 5 mL ampoule Oral > Liquid: 200 mg + 40 mg per 5 mL oral liquid Oral > Solid: 100 mg + 20 mg tablet; 400 mg + 80 mg tablet; 800 mg + 160 mg tablet	Bacterial infection of unspecified site

## Terizidone

Section	Indications
Antituberculosis medicines	Therapeutic equivalent to cycloserine for Multi-drug resistant Mycobacterium tuberculosis

## Tetracycline

Section	Indications
Access group antibiotics Oral > Solid: 250 mg (hydrochloride)	Bacterial infection of unspecified site

## Tigecycline

Section	Indications
Reserve group antibiotics Parenteral > General injections > IV: 50 mg in vial powder for injection	Other specified bacterial diseases

## Trimethoprim

Section	Indications
Access group antibiotics	First choice
Oral > Liquid: 50 mg per mL	Infectious cystitis
Oral > Solid: 100 mg; 200 mg	

## Vancomycin

Section	Indications
Watch group antibiotics	First choice
Parenteral > General injections > IV: 250 mg in vial (as hydrochloride) powder for injection	co-prescribed with <b>ceftazidime</b>
	<b>Endophthalmitis</b>
	co-prescribed with <b>ceftriaxone</b>
	<b>Endophthalmitis</b>
	Other indications
	<b>Methicillin resistant Staphylococcus aureus</b>